vs
Side-by-side financial comparison of CLEANSPARK, INC. (CLSK) and AMICUS THERAPEUTICS, INC. (FOLD). Click either name above to swap in a different company.
AMICUS THERAPEUTICS, INC. is the larger business by last-quarter revenue ($185.2M vs $181.2M, roughly 1.0× CLEANSPARK, INC.). AMICUS THERAPEUTICS, INC. runs the higher net margin — 0.9% vs -209.0%, a 209.9% gap on every dollar of revenue. On growth, AMICUS THERAPEUTICS, INC. posted the faster year-over-year revenue change (23.7% vs 11.6%). AMICUS THERAPEUTICS, INC. produced more free cash flow last quarter ($16.0M vs $-198.1M). Over the past eight quarters, CLEANSPARK, INC.'s revenue compounded faster (106.4% CAGR vs 29.5%).
CleanSpark, Inc. is a U.S.-headquartered sustainable technology company operating two core business segments: low-carbon Bitcoin mining powered primarily by renewable and stranded energy resources, and end-to-end microgrid design, deployment, and operation services for commercial, industrial, and public sector clients across North America.
Amicus Therapeutics, Inc. is a public American biopharmaceutical company based in Philadelphia, Pennsylvania. The company went public in 2007 under the Nasdaq trading symbol FOLD. This followed a 2006 planned offering and subsequent withdrawal, which would have established the trading symbol as AMTX Prior to their IPO, Amicus was funded by a variety of venture capital firms including Radius Ventures, Canaan Partners and New Enterprise Associates.
CLSK vs FOLD — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $181.2M | $185.2M |
| Net Profit | $-378.7M | $1.7M |
| Gross Margin | 47.2% | 85.7% |
| Operating Margin | -174.7% | 8.6% |
| Net Margin | -209.0% | 0.9% |
| Revenue YoY | 11.6% | 23.7% |
| Net Profit YoY | -253.5% | -88.5% |
| EPS (diluted) | — | $0.00 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $181.2M | $185.2M | ||
| Q3 25 | — | $169.1M | ||
| Q2 25 | — | $154.7M | ||
| Q1 25 | — | $125.2M | ||
| Q4 24 | — | $149.7M | ||
| Q3 24 | $89.3M | $141.5M | ||
| Q2 24 | $104.1M | $126.7M | ||
| Q1 24 | $111.8M | $110.4M |
| Q4 25 | $-378.7M | $1.7M | ||
| Q3 25 | — | $17.3M | ||
| Q2 25 | — | $-24.4M | ||
| Q1 25 | — | $-21.7M | ||
| Q4 24 | — | $14.7M | ||
| Q3 24 | $-62.2M | $-6.7M | ||
| Q2 24 | $-236.2M | $-15.7M | ||
| Q1 24 | $126.7M | $-48.4M |
| Q4 25 | 47.2% | 85.7% | ||
| Q3 25 | — | 88.5% | ||
| Q2 25 | — | 90.2% | ||
| Q1 25 | — | 90.7% | ||
| Q4 24 | — | 90.1% | ||
| Q3 24 | 36.0% | 90.6% | ||
| Q2 24 | 56.6% | 91.1% | ||
| Q1 24 | 69.3% | 87.7% |
| Q4 25 | -174.7% | 8.6% | ||
| Q3 25 | — | 20.3% | ||
| Q2 25 | — | -6.1% | ||
| Q1 25 | — | -6.3% | ||
| Q4 24 | — | 10.7% | ||
| Q3 24 | -73.5% | 15.3% | ||
| Q2 24 | -239.2% | 11.8% | ||
| Q1 24 | — | -25.1% |
| Q4 25 | -209.0% | 0.9% | ||
| Q3 25 | — | 10.2% | ||
| Q2 25 | — | -15.8% | ||
| Q1 25 | — | -17.3% | ||
| Q4 24 | — | 9.8% | ||
| Q3 24 | -69.6% | -4.8% | ||
| Q2 24 | -226.9% | -12.4% | ||
| Q1 24 | 113.4% | -43.9% |
| Q4 25 | — | $0.00 | ||
| Q3 25 | — | $0.06 | ||
| Q2 25 | — | $-0.08 | ||
| Q1 25 | — | $-0.07 | ||
| Q4 24 | — | $0.05 | ||
| Q3 24 | — | $-0.02 | ||
| Q2 24 | — | $-0.05 | ||
| Q1 24 | — | $-0.16 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $458.1M | $293.5M |
| Total DebtLower is stronger | $1.8B | $392.7M |
| Stockholders' EquityBook value | $1.4B | $274.2M |
| Total Assets | $3.3B | $949.9M |
| Debt / EquityLower = less leverage | 1.29× | 1.43× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $458.1M | $293.5M | ||
| Q3 25 | — | $263.8M | ||
| Q2 25 | — | $231.0M | ||
| Q1 25 | — | $250.6M | ||
| Q4 24 | — | $249.9M | ||
| Q3 24 | $121.2M | $249.8M | ||
| Q2 24 | $126.1M | $260.1M | ||
| Q1 24 | — | $239.6M |
| Q4 25 | $1.8B | $392.7M | ||
| Q3 25 | — | $392.0M | ||
| Q2 25 | — | $391.3M | ||
| Q1 25 | — | $390.7M | ||
| Q4 24 | — | $390.1M | ||
| Q3 24 | $7.2M | $389.5M | ||
| Q2 24 | $1.3M | $388.9M | ||
| Q1 24 | $5.1M | $388.4M |
| Q4 25 | $1.4B | $274.2M | ||
| Q3 25 | — | $230.4M | ||
| Q2 25 | — | $204.3M | ||
| Q1 25 | — | $193.6M | ||
| Q4 24 | — | $194.0M | ||
| Q3 24 | $1.8B | $178.8M | ||
| Q2 24 | $1.4B | $132.5M | ||
| Q1 24 | $1.5B | $130.7M |
| Q4 25 | $3.3B | $949.9M | ||
| Q3 25 | — | $868.8M | ||
| Q2 25 | — | $815.3M | ||
| Q1 25 | — | $789.8M | ||
| Q4 24 | — | $785.0M | ||
| Q3 24 | $2.0B | $786.6M | ||
| Q2 24 | $1.5B | $749.5M | ||
| Q1 24 | $1.5B | $721.8M |
| Q4 25 | 1.29× | 1.43× | ||
| Q3 25 | — | 1.70× | ||
| Q2 25 | — | 1.92× | ||
| Q1 25 | — | 2.02× | ||
| Q4 24 | — | 2.01× | ||
| Q3 24 | 0.00× | 2.18× | ||
| Q2 24 | 0.00× | 2.93× | ||
| Q1 24 | 0.00× | 2.97× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-161.1M | $16.3M |
| Free Cash FlowOCF − Capex | $-198.1M | $16.0M |
| FCF MarginFCF / Revenue | -109.3% | 8.6% |
| Capex IntensityCapex / Revenue | 20.4% | 0.2% |
| Cash ConversionOCF / Net Profit | — | 9.62× |
| TTM Free Cash FlowTrailing 4 quarters | $-626.9M | $29.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-161.1M | $16.3M | ||
| Q3 25 | — | $35.7M | ||
| Q2 25 | — | $-26.5M | ||
| Q1 25 | — | $7.8M | ||
| Q4 24 | — | $-3.9M | ||
| Q3 24 | $-233.7M | $-23.0M | ||
| Q2 24 | $-58.4M | $22.7M | ||
| Q1 24 | $-44.8M | $-29.7M |
| Q4 25 | $-198.1M | $16.0M | ||
| Q3 25 | — | $35.3M | ||
| Q2 25 | — | $-28.9M | ||
| Q1 25 | — | $7.5M | ||
| Q4 24 | — | $-4.2M | ||
| Q3 24 | $-299.8M | $-23.3M | ||
| Q2 24 | $-68.7M | $21.6M | ||
| Q1 24 | $-60.3M | $-31.5M |
| Q4 25 | -109.3% | 8.6% | ||
| Q3 25 | — | 20.9% | ||
| Q2 25 | — | -18.7% | ||
| Q1 25 | — | 6.0% | ||
| Q4 24 | — | -2.8% | ||
| Q3 24 | -335.8% | -16.5% | ||
| Q2 24 | -66.0% | 17.0% | ||
| Q1 24 | -54.0% | -28.5% |
| Q4 25 | 20.4% | 0.2% | ||
| Q3 25 | — | 0.2% | ||
| Q2 25 | — | 1.6% | ||
| Q1 25 | — | 0.2% | ||
| Q4 24 | — | 0.2% | ||
| Q3 24 | 74.0% | 0.3% | ||
| Q2 24 | 9.9% | 0.9% | ||
| Q1 24 | 13.8% | 1.6% |
| Q4 25 | — | 9.62× | ||
| Q3 25 | — | 2.06× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -0.27× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -0.35× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CLSK
Segment breakdown not available.
FOLD
| Other | $105.8M | 57% |
| Galafold | $64.8M | 35% |
| Pombiliti Opfolda | $14.6M | 8% |
